Biological aging is a complex, multifaceted process characterized by the gradual decline of physiological and cognitive functions over time. While researchers have identified certain hallmarks — such as cellular damage and genomic instability — the underlying mechanisms remain incompletely understood. Resilience mechanisms naturally decline with age, allowing damage to accumulate and contributing to frailty and disease. Understanding both repair processes and damage accumulation is crucial for comprehending the variability in how individuals age.
Cellular senescence occurs when cells cease dividing permanently following stress triggers such as DNA damage or telomere shortening. These dormant cells secrete pro-inflammatory factors, resist apoptosis, and accumulate in tissues over time — contributing to conditions including osteoarthritis, type 2 diabetes, and Alzheimer's disease. Measuring senescence in humans presents ongoing challenges due to heterogeneous triggers and insufficient validated biomarkers, but progress in this area is advancing rapidly.
Epigenetic clocks, which monitor age-related changes in DNA methylation patterns, represent one of the most promising biomarkers for quantifying biological aging. Early-life epigenetic modifications can shift from adaptive to harmful over time. Measuring methylation patterns provides insight into biological age independent of chronological age, and may eventually guide interventions aimed at slowing the aging process at the molecular level.
Cellular maintenance processes, including autophagy — the mechanism by which cells degrade and recycle damaged components — become less efficient with advancing age. Compounds such as rapamycin, spermidine, and resveratrol have been studied for their capacity to enhance autophagy and support cellular health. Developing reliable human autophagy measurement assays remains technically challenging but could serve as valuable aging biomarkers in future clinical research.
Developing reliable measures of biological aging represents a critical priority for advancing geriatric and preventive medicine. Such measures would enable clinicians to identify high-risk patients earlier and intervene before multiple age-related diseases develop simultaneously, shifting care from reactive treatment to proactive health preservation.